Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410344 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01410344 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 20 participants.
The verdict
NCT01410344, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection. In particular, the trial will focus on the 100-day non-relapse mortality as an indicator of the safety of transplant in this patient population. Correlative assays will focus upon the incidence of infectious complications in this patient population, the evolution of HIV infection and immunological reconstitution. Where feasible (and when this can be accomplished without compromise of either the donor quality or the timeliness of transplantation), an attempt will be made to identify donors who are homozygotes for the delta32 mutation for CCR5.
Interventions
- DRUG Fludarabine and Busulfan
- DRUG Fludarabine and Melphalan
- DRUG Busulfan and Fludarabine
- DRUG Cyclophosphamide and Total Body Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-09 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01410344
The ClinicalTrials.gov registry entry for NCT01410344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine and Busulfan is the first listed.
NCT01410344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01410344 about?
NCT01410344 is a clinical study titled "Allogeneic Transplant in HIV Patients (BMT CTN 0903)". The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection. In particular, the trial will focus on the 100-day non-relapse mortality as an indicator of the safety of tran...
What is the current status of trial NCT01410344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2018-06.
What interventions are being tested in trial NCT01410344?
The interventions under investigation include: Fludarabine and Busulfan (DRUG), Fludarabine and Melphalan (DRUG), Busulfan and Fludarabine (DRUG), Cyclophosphamide and Total Body Irradiation (DRUG).
Who is sponsoring clinical trial NCT01410344?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.